IRIS
MOR, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.154
AS - Asia 11.750
EU - Europa 9.465
SA - Sud America 1.617
AF - Africa 594
Continente sconosciuto - Info sul continente non disponibili 395
OC - Oceania 13
Totale 37.988
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.746
SG - Singapore 4.213
CN - Cina 3.247
IT - Italia 2.111
VN - Vietnam 1.811
FI - Finlandia 1.440
IE - Irlanda 1.296
BR - Brasile 1.258
SE - Svezia 1.163
DE - Germania 948
HK - Hong Kong 868
UA - Ucraina 654
BD - Bangladesh 419
FR - Francia 397
ZA - Sudafrica 397
NL - Olanda 360
GB - Regno Unito 288
TR - Turchia 288
CA - Canada 253
IN - India 212
RU - Federazione Russa 189
AT - Austria 188
AR - Argentina 123
CI - Costa d'Avorio 90
JP - Giappone 87
BE - Belgio 86
ES - Italia 80
MX - Messico 78
PL - Polonia 77
IQ - Iraq 76
KR - Corea 73
ID - Indonesia 66
EC - Ecuador 57
CZ - Repubblica Ceca 49
PH - Filippine 47
PK - Pakistan 47
CO - Colombia 41
TH - Thailandia 41
VE - Venezuela 40
CL - Cile 29
JO - Giordania 29
LT - Lituania 28
MA - Marocco 28
UZ - Uzbekistan 28
PY - Paraguay 25
SA - Arabia Saudita 22
TW - Taiwan 20
MY - Malesia 19
KE - Kenya 18
UY - Uruguay 16
PE - Perù 15
HN - Honduras 14
IL - Israele 14
NP - Nepal 14
RO - Romania 14
AZ - Azerbaigian 13
TN - Tunisia 13
ET - Etiopia 12
HU - Ungheria 12
EG - Egitto 11
HR - Croazia 11
JM - Giamaica 11
OM - Oman 11
PA - Panama 10
BY - Bielorussia 9
IR - Iran 9
AU - Australia 8
BO - Bolivia 8
CR - Costa Rica 8
DZ - Algeria 8
KG - Kirghizistan 8
LB - Libano 8
PS - Palestinian Territory 8
SY - Repubblica araba siriana 8
AL - Albania 7
DO - Repubblica Dominicana 7
EU - Europa 7
KZ - Kazakistan 7
NI - Nicaragua 7
RS - Serbia 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
CH - Svizzera 6
NO - Norvegia 6
EE - Estonia 5
MD - Moldavia 5
QA - Qatar 5
SV - El Salvador 5
AO - Angola 4
CY - Cipro 4
GE - Georgia 4
LU - Lussemburgo 4
LV - Lettonia 4
SI - Slovenia 4
SN - Senegal 4
BH - Bahrain 3
GR - Grecia 3
GY - Guiana 3
MN - Mongolia 3
PR - Porto Rico 3
Totale 37.552
Salva come PNG Salva come JPEG
Città #
Singapore 2.113
Ashburn 1.567
San Jose 1.306
Chandler 1.285
Dublin 1.285
Dallas 996
Santa Clara 955
Hong Kong 821
Beijing 771
Jacksonville 754
Parma 593
Ho Chi Minh City 565
Council Bluffs 468
Dearborn 456
Ann Arbor 440
Boardman 439
Hanoi 388
Johannesburg 371
Los Angeles 330
Nanjing 319
New York 305
Lauterbourg 250
Princeton 248
Munich 241
Izmir 233
Shanghai 227
Wilmington 190
Hefei 179
Helsinki 162
San Mateo 162
Milan 156
Vienna 152
São Paulo 127
Toronto 127
Bremen 113
Columbus 110
Shenyang 109
Buffalo 106
Moscow 98
Bologna 93
Nanchang 93
Abidjan 90
Jinan 88
Hebei 86
Kunming 85
Haiphong 79
Turku 77
Brussels 76
Da Nang 76
The Dalles 72
Tokyo 71
Frankfurt am Main 70
Seattle 66
London 65
Düsseldorf 63
Changsha 62
Des Moines 60
Rome 60
Warsaw 58
Chicago 55
Guangzhou 55
Montreal 55
Phoenix 52
Brooklyn 51
Jiaxing 49
Modena 47
Tianjin 47
Houston 46
Jakarta 46
Pune 45
Seoul 45
Brescia 40
Denver 40
Atlanta 39
Orem 39
Rio de Janeiro 38
Woodbridge 38
Stockholm 36
Chennai 35
Fremont 33
Naples 33
Nuremberg 33
San Francisco 33
Baghdad 30
Belo Horizonte 30
Norwalk 30
Zhengzhou 29
Mexico City 28
Dhaka 26
Amman 25
Biên Hòa 25
Can Tho 25
Hangzhou 25
Poplar 25
Amsterdam 24
Grafing 24
Ankara 23
Palermo 23
Brno 22
Curitiba 22
Totale 22.473
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 355
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 286
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 279
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 263
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 257
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 251
Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats 243
Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats 239
2-Aminobenzimidazoles as new potent H3-antagonists 231
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 226
Analysis of Structure-Activity Relationships for MT2 Selective Antagonists by Melatonin MT1 and MT2 Receptor Models 223
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 222
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 222
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 221
Social stress-induced depressive-like symptoms and changes in gut microbial and lipidomic profiles are prevented by pharmacological inhibition of FAAH activity in male rats 220
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 219
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 219
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 218
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 216
Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694, in a rodent model of trait anxiety 215
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 214
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 213
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 213
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 210
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 209
2-N-Acylaminoalkylindoles: Design and Quantitative Structure-Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists 208
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 205
Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. 201
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 200
Aminobenzimidazoles as new potent H3-antagonists 200
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 199
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 197
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 196
Alchilammidi tricicliche: ligandi selettivi dei recettori melatoninergici MT1 e MT2 196
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 196
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 193
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 193
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 190
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 188
Functional modulation of the human gut microbiome by bacteria vehicled by cheese 186
5-benzylidene-hydantoins as new inhibitors of cell proliferation 184
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 183
Chiral Recognition of Flexible Melatonin Receptor Ligands Induced by Conformational Equilibria 183
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 182
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 181
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 181
3-Aminoazetidin-2-one Derivatives asN-Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration 180
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 180
A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo 180
4-(1,2-benzisothiazol-3-)alkanoic and phenylalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic activities 179
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 179
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 178
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 177
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 176
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 176
Steps towards sustainable solid phase peptide synthesis: use and recovery ofN-octyl pyrrolidone 176
2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists. 175
Chapter 9: Natural and Synthetic Agents That Target Intracellular Monoacylglycerol Lipase (MGL) Activity 173
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 170
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 169
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 169
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 166
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 166
N-(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability 165
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 165
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility 164
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 163
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 161
Chiral NMR discrimination of the diastereoisomeric salts of the H(3)-antagonist 2-[3-(1H-imidazol-4-ylmethyl)piperidin-1-yl]-1H-benzimidazole. 161
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 161
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 160
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 158
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 158
Antioxidant and cytoprotective activity of indole derivatives related to melatonin 156
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 155
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 155
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 155
Palladium Catalyst Recycling for Heck-Cassar-Sonogashira Cross-Coupling Reactions in Green Solvent/Base Blend 155
Mannich base derivatives as novel EGFR irreversible inhibitors 154
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 154
Brain Pharmacokinetics of Non-Imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrospray-Mass Spectrometry and ex vivo Binding Study in Rats 153
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 153
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 153
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 152
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 152
Synthesis and 3D-QSAR Analysis of H3 Receptor Antagonists Containing a Neutral Heterocyclic Polar Group 151
N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands 151
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 151
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 151
Biological studies on 1,2-benzisothiazole derivatives. V. Antimicrobial properties of N-alkanoic, N-arylalkanoic and N-aryloxyalkanoic derivatives of 1,2-benzisothiazolin-3-one: QSAR study and genotoxicity evaluation 151
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 151
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 150
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 149
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 149
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 149
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 148
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 147
Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. 147
Development of a GPCR model for SAR interpretation of classical and new H3 antagonists 146
Toward the Definition of Stereochemical Requirements for MT(2)-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. 145
Totale 18.594
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.737
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.737
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.287 0 37 14 121 85 40 149 175 91 102 90 383
2022/20235.095 551 503 311 392 486 607 46 313 1.575 60 188 63
2023/20241.980 109 148 56 68 145 457 166 159 78 124 201 269
2024/20256.618 169 350 436 424 600 739 303 354 836 650 590 1.167
2025/202614.753 1.235 1.584 1.832 1.405 1.951 817 1.557 449 1.750 1.065 662 446
2026/20271.071 357 714 0 0 0 0 0 0 0 0 0 0
Totale 37.988